| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.27▼ | 1.27▼ | 1.27▼ | 1.22▲ | 1.30▼ |
| MA10 | 1.27▼ | 1.25▼ | 1.25▼ | 1.19▲ | 1.36▼ |
| MA20 | 1.25▼ | 1.22▲ | 1.20▲ | 1.30▼ | 1.57▼ |
| MA50 | 1.19▲ | 1.23▲ | 1.24▼ | 1.44▼ | 2.31▼ |
| MA100 | 1.29▼ | 1.35▼ | 1.35▼ | 1.71▼ | 2.63▼ |
| MA200 | 1.41▼ | 1.45▼ | 1.45▼ | 2.29▼ | 5.55▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.004▼ | 0.006▲ | 0.010▲ | 0.001▲ | 0.007▲ |
| RSI | 49.543▼ | 51.359▲ | 51.397▲ | 43.774▼ | 38.204▼ |
| STOCH | 62.500 | 60.658 | 60.632 | 41.410 | 17.895▼ |
| WILL %R | -75.000 | -51.724 | -51.724 | -57.762 | -83.373▼ |
| CCI | -59.453 | -2.988 | 13.244 | -23.381 | -108.507▼ |
|
Tuesday, February 17, 2026 04:14 AM
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) (“Cyclerion” or "Company”), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory ...
|
|
Monday, February 02, 2026 09:14 AM
By David Bautz, PhD NASDAQ:CYCN READ THE FULL CYCN RESEARCH REPORT Initiating Coverage We are initiating coverage of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) with a valuation of $8.00. Cyclerion is ...
|
|
Tuesday, January 06, 2026 10:30 PM
The following slide deck was published by Cyclerion Therapeutics, Inc. in conjunction with this event.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/02/26 | 1.21 | 1.235 | 1.21 | 1.235 | 29,015 |
| 13/02/26 | 1.19 | 1.33 | 1.1662 | 1.25 | 58,614 |
| 12/02/26 | 1.22 | 1.27 | 1.18 | 1.21 | 40,560 |
| 11/02/26 | 1.14 | 1.27 | 1.1206 | 1.22 | 52,753 |
| 10/02/26 | 1.185 | 1.215 | 1.16 | 1.17 | 19,689 |
| 09/02/26 | 1.11 | 1.19 | 1.0266 | 1.17 | 82,595 |
| 06/02/26 | 1.105 | 1.12 | 1.06 | 1.10 | 76,300 |
| 05/02/26 | 1.21 | 1.23 | 1.07 | 1.08 | 133,312 |
| 04/02/26 | 1.25 | 1.28 | 1.24 | 1.24 | 48,600 |
| 03/02/26 | 1.37 | 1.52 | 1.24 | 1.24 | 189,100 |
|
|
||||
|
|
||||
|
|